UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm

Antimicrobial agents and chemotherapy, 2018-07, Vol.62 (7)

2018

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Antimicrobial agents and chemotherapy, 2018-06, Vol.62 (6)

2018

Volltextzugriff (PDF)

Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data"

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Antimicrobial agents and chemotherapy, 2023-04, Vol.67 (4), p.e0221321-e0221321

2023

Volltextzugriff (PDF)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Antimicrobial agents and chemotherapy, 2018-06, Vol.62 (6)

2018

Volltextzugriff (PDF)

Drug‐Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned

Journal of clinical pharmacology, 2019-08, Vol.59 (8), p.1035-1043

2019

Volltextzugriff (PDF)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems

Antimicrobial agents and chemotherapy, 2021-11, Vol.65 (12), p.e0012221

2021

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

Antimicrobial agents and chemotherapy, 2017-02, Vol.61 (2)

2017

Volltextzugriff (PDF)

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs

Current opinion in pharmacology, 2017-10, Vol.36, p.139-145

2017

Volltextzugriff (PDF)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Antimicrobial agents and chemotherapy, 2017-11, Vol.61 (11)

2017

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

Antimicrobial agents and chemotherapy, 2019-08, Vol.63 (8)

2019

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

Antimicrobial agents and chemotherapy, 2020-09, Vol.64 (10)

2020

Volltextzugriff (PDF)

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes

Antimicrobial agents and chemotherapy, 2018-10, Vol.62 (10)

2018

Volltextzugriff (PDF)

Time for Precision: A World Without Susceptibility Breakpoints

Open forum infectious diseases, 2018-12, Vol.5 (12), p.ofy282-ofy282

2018

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

Blood, 2018-11, Vol.132 (Supplement 1), p.2071-2071

2018

Volltextzugriff (PDF)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S569-S570

2019

Volltextzugriff (PDF)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S426-S427

2018

Volltextzugriff (PDF)

Traditional PK-PD Indices for Efficacy – Can We Do Better?

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S298-S298

2017

Volltextzugriff (PDF)

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S422-S423

2018

Volltextzugriff (PDF)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection

Open forum infectious diseases, 2018-11, Vol.5 (suppl_1), p.S427-S428

2018

Volltextzugriff (PDF)

Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S473-S473

2017

Volltextzugriff (PDF)

A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration

Open forum infectious diseases, 2017-10, Vol.4 (suppl_1), p.S529-S530

2017

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(33)
Buchkapitel
(1)

Sprache

Englisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Pharmacology & Pharmacy
(15)
Microbiology
(13)
Abstracts
(7)
Humans
(7)
Pharmacology
(7)
Microbial Sensitivity Tests
(6)
Clinical Therapeutics
(4)
Pharmacokinetics-Pharmacodynamics
(4)
Animals
(3)
Anti-Bacterial Agents
(3)
Anti-Bacterial Agents - Pharmacology
(3)
Anti-Bacterial Agents - Therapeutic Use
(3)
Candida Albicans
(3)
Echinocandins
(3)
Female
(3)
Omadacycline
(3)
Streptococcus Pneumoniae
(3)
Acenaphthenes
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data"

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Drug‐Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

Ensuring quality pharmacokinetic analyses in antimicrobial drug development programs

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes

Time for Precision: A World Without Susceptibility Breakpoints

Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

Traditional PK-PD Indices for Efficacy – Can We Do Better?

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection

Emerging Candida glabrata Resistance and Echinocandin Dosing: A Call to Arms

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF) Penetration

Suchergebnisse filtern